Composition and nutritional supplement for reducing blood sugar and blood fat of dogs and cats as well as preparation method and application of composition and nutritional supplement

Abstract

The invention discloses a composition for reducing blood sugar and blood fat of dogs and cats, a nutritional supplement, a preparation method and application, and belongs to the technical field of animal health care product preparation. The composition is prepared from ginsenoside and a perilla seed extract according to a specific proportion, and the effects of reducing the content of triglyceride and total cholesterol of high-fat liver cells induced by oleic acid (OA), increasing high-density lipoprotein cholesterol and reducing low-density lipoprotein cholesterol are achieved through a synergistic effect. The glucose consumption of high-glucose induced damaged liver cells is improved, and the oxidative stress caused by high glucose is retarded. The nutritional supplement is prepared by mixing the ginsenoside and the purple perilla seed extract according to a certain proportion and adding the additive, so that hyperlipidemia and hyperglycemia of dogs and cats can be improved to a certain extent, the health level of dogs and cats can be improved, and the nutritional supplement has a wide application prospect.

Description

Technical Field

[0001] The present invention relates to the technical field of pet health care, and particularly relates to an active substance composition for reducing blood sugar and blood lipids in dogs and cats and its application. Background Art

[0002] Pets have become important companions in people's lives and an important spiritual sustenance. However, this can also cause problems such as overfeeding and excessive nutrition, leading to symptoms such as obesity in pets. The main cause of pet obesity is the imbalance between energy intake and consumption caused by high-fat diet intake and abnormal lipid accumulation. Obesity is an important factor inducing diabetes and seriously endangers the health of dogs and cats. The occurrence of obesity also increases the risk of other diseases, such as heart disease, joint problems, and respiratory diseases, etc. Preventing high blood fat and high blood sugar in dogs and cats can be achieved to a certain extent by controlling diet and increasing exercise.

[0003] Saponins are a class of glycosides with triterpenoid or spirostanoid compounds as aglycones. According to the different aglycones, they are mostly divided into triterpenoid saponins and steroidal saponins. Saponins are widely present in Chinese medicinal materials. Studies have found that they have biological activities such as anti-inflammatory, antioxidant stress, liver protection and lipid-lowering, blood sugar-lowering, and anti-tumor, and have high development potential and utilization value in disease prevention and treatment. Ginseng is a traditional herb that has been widely used in East Asia for more than 4,000 years to treat various diseases. The sterol compound in ginseng - ginsenoside is its main active ingredient and plays a medicinal value in cardiovascular, endocrine, immune systems, and neuroprotection. It is reported that ginsenosides can reduce body weight, improve glucose and lipid metabolism, and reduce triglyceride accumulation.

[0004] Perilla is an important herb that is both medicine and food. It not only has a unique fragrance, but also its rich content of fatty acids, flavonoids, and phenolic active substances play important roles in various biological functions such as antioxidant, immune enhancement, antibacterial, and anti-inflammatory. Perilla seed extract is a common plant extract, and its main active ingredients are divided into volatile oils and non-volatile components. Components such as linalool, perillaldehyde, and limonene in the volatile oils have antioxidant effects, can scavenge free radicals, and protect cells from oxidative damage. In addition to the volatile oil components, perilla seed extract also contains non-volatile components such as polysaccharides, proteins, amino acids, and trace elements, and these components also have certain biological activities. The polysaccharide components have immunomodulatory effects, can enhance the immune function of the body, and improve resistance. Certain components in perilla seed extract can lower blood lipid levels, prevent the occurrence of atherosclerosis, and are beneficial to cardiovascular health. Research shows that perilla seed extract has a protective effect on the liver and can reduce liver damage.

[0005] At present, many existing patents on the market have proposed to prevent or alleviate high fat and high sugar in pets by adding a certain amount of active substances to pet food. For example: Patent CN118661811A proposes a new type of pet lipid-lowering biscuit containing Elaeagnus angustifolia fruit powder, which has a certain lipid-lowering effect. Patent CN113180145A proposes a pet food with the functions of reducing blood sugar and blood lipids, containing Cyperus esculentus, Aronia melanocarpa, and Lycium barbarum, which has the functions of reducing low-density cholesterol, controlling blood sugar, preventing diabetes, and antioxidation. Patent CN108497194A proposes a dog-use green tea powder feed with lipid-lowering effects, containing basic feed and green tea powder, which can effectively control the weight of dogs, significantly reduce the levels of TC and TG in animal blood, reduce the incidence of cardiovascular diseases, and avoid the physical harm caused by medication to pets.

[0006] Ginsenosides and Perilla seed extracts have been widely used as raw materials and functional components in the development of health foods for humans. They are used for anti-tumor, antioxidant, prevention of cardiovascular and cerebrovascular diseases, etc. Although they have begun to be applied in dog and cat pet foods at present, their specific functions are not yet clear. The present invention analyzes the gene expression and metabolic pathway changes caused by high fat and high sugar in pets, and points out the effects of ginsenosides and Perilla seed extracts in reducing blood sugar and blood lipids in pets. Summary of the Invention

[0007] Aiming at the limitations of the prior art, the purpose of the present invention is to provide an active substance composition for reducing blood sugar and blood lipids in dogs and cats, aiming to alleviate the symptoms of high fat and high sugar in obese pets and maintain the health of pets.

[0008] To achieve the above purpose, the present invention adopts the following technical solutions:

[0009] In the first aspect of the present invention, there is provided an active substance composition for reducing blood sugar and blood lipids in dogs and cats, which is composed of ginsenosides and Perilla seed extracts; the weight ratio of the two raw materials of ginsenosides and Perilla seed extracts in the active substance composition is: ginsenosides: Perilla seed extracts = 2:(1 - 1.5).

[0010] Preferably, the weight ratio of the two raw materials of ginsenosides and Perilla seed extracts in the active substance composition is: ginsenosides: Perilla seed extracts = 2:1.

[0011] In the second aspect of the present invention, there is provided the application of the above-mentioned active substance composition in the preparation of pet feed or pet health products.

[0012] In the third aspect of the present invention, there is provided the application of the above-mentioned active substance composition in the preparation of pet feed and pet health products for reducing blood lipids in dogs and cats.

[0013] In the fourth aspect of the present invention, there is provided an application of the above active substance composition in the preparation of pet feeds and pet health products for reducing blood glucose in dogs and cats.

[0014] In the fifth aspect of the present invention, there is provided an application of the above active substance composition in the preparation of pet feeds and pet health products for improving obesity in dogs and cats.

[0015] A nutritional supplement for improving pet obesity is composed of ginsenoside, perilla seed extract, chicken powder, mulberry leaf powder, hawthorn powder, and propolis; the mass fractions of each component are as follows:

[0016] Ginsenoside 0.5 - 2 parts, perilla seed extract 0.5 - 1 part, chicken powder 70 - 80 parts, mulberry leaf powder 8 - 12 parts, hawthorn powder 8 - 10 parts, propolis 0.01 - 0.03 parts, glutamic acid 0.1 - 0.3 parts, vitamin C 0.01 - 0.03 parts, α-linolenic acid 0.5 - 0.7 parts, eicosapentaenoic acid (EPA) 0.01 - 0.04 parts.

[0017] A method for preparing a nutritional supplement for improving pet obesity is carried out according to the following steps:

[0018] Step (1): Weigh ginsenoside and perilla seed extract according to a ratio of 1:1.5, mix them, stir with a blender at a speed of 300 r / min for 20 min, and pass through a 100-mesh sieve to obtain a mixed powder;

[0019] Step (2): Add water to the mixed powder, and stir the raw and auxiliary materials and glyceryl monostearate with a homogenizer at a speed of 11000 r / min for 4 min to obtain a raw and auxiliary material mixture;

[0020] Step (3): Directly press the raw and auxiliary material mixture with a rotary tablet press,

[0021] In step (2), the raw materials are 80 parts of chicken powder, 5 parts of mulberry leaf powder, 4 parts of hawthorn powder, 0.02 parts of propolis, and 6 parts of water;

[0022] In step (2), the auxiliary materials are 0.1 part of glutamic acid, 0.01 part of vitamin C, 0.05 part of α-linolenic acid, 0.01 part of eicosapentaenoic acid (EPA), 0.02 part of vitamin A, and 0.2 part of glyceryl monostearate.

[0023] The composition of the present invention realizes its function through specific ratios of ginsenoside and perilla seed extract through the following mechanism of action:

[0024] 1. Inhibit the activities of enzymes such as α-amylase and α-glucosidase.

[0025] 2. Reduce the contents of triglyceride, cholesterol, and low-density lipoprotein cholesterol in the hepatocytes of hyperlipidemic dogs, and increase the content of high-density lipoprotein cholesterol in the hepatocytes of hyperlipidemic dogs. Reduce the excessive lipid accumulation in the hepatocytes of hyperlipidemic dogs.

[0026] 3. Promote the glucose consumption of dog hepatocytes damaged by high glucose.

[0027] 4. Alleviate the oxidative stress of dog hepatocytes damaged by high glucose.

[0028] The composition of the present invention has the following beneficial effects through specific proportions of ginsenosides and perilla seed extract:

[0029] 1. The present invention is formulated from ginsenosides and perilla seed extract, and has remarkable effects in reducing total cholesterol, triglyceride, and low-density lipoprotein cholesterol, and increasing high-density lipoprotein cholesterol.

[0030] 2. The active substance composition provided by the present invention has remarkable effects in increasing glucose consumption and alleviating oxidative stress damage.

[0031] 3. The hypoglycemic and lipid-lowering composition formula provided by the present invention is mainly composed of natural substances, with safe ingredients, no side effects, and a small metabolic burden on the liver and kidneys. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] The drawings constituting a part of the present invention are used to provide a further understanding of the present invention. The schematic embodiments and descriptions thereof of the present invention are used to explain the present invention and do not constitute an improper limitation of the present invention.

[0033] In the drawings:

[0034] Figure 1 Shows the effects of ginsenosides and perilla seed extract in the present invention on the activities of (A) α-amylase and (B) α-glucosidase.

[0035] Figure 2 Shows the effects of ginsenosides, perilla seed extract and their combinations in the present invention on lipid accumulation indexes. (A) Effects of ginsenosides, perilla seed extract and their combinations on triglyceride (TG) concentration; (B) Effects of ginsenosides, perilla seed extract and their combinations on total cholesterol (TC) concentration; (C) Effects of ginsenosides, perilla seed extract and their combinations on high-density lipoprotein cholesterol (HDL-C) concentration; (D) Effects of ginsenosides, perilla seed extract and their combinations on low-density lipoprotein cholesterol (LDL-C) concentration.

[0036] Figure 3 Shows the effects of ginsenosides, perilla seed extract and their combinations in the present invention on the glucose consumption of cells.

[0037] Figure 4This is the effect of ginsenosides, perilla seed extract and their combination on oxidative stress indexes in the present invention. (A) Effect of ginsenosides, perilla seed extract and their combination on the concentration of superoxide dismutase (SOD); (B) Effect of ginsenosides, perilla seed extract and their combination on the concentration of malondialdehyde (MDA). (C) Effect of ginsenosides, perilla seed extract and their combination on catalase (CAT).

[0038] Figure 5 These are the volcano plots and bar charts of differentially expressed genes among groups in the present invention. (A) Volcano plot of differentially expressed genes before and after treatment with the active substance composition; (B) Volcano plot of differentially expressed genes of the active substance composition and ginsenosides alone; (C) Volcano plot of differentially expressed genes before and after treatment with perilla seed extract; (D) Differentially expressed genes in each treatment group. Detailed implementation manners

[0039] It should be noted that, without conflict, the embodiments in the present invention and the features in the embodiments can be combined with each other.

[0040] The present invention will be described in detail below with reference to the drawings and in combination with embodiments.

[0041] Example 1

[0042] In vitro hypoglycemic and lipid-lowering activities

[0043] 0.1 mL of α-amylase (2 U / mL) and 0.2 mL of ginsenosides were successively added to a 15 mL centrifuge tube and kept at 37 °C for 15 min. Then 0.2 mL of starch solution (1%) was added and kept at 37 °C for 20 min. After that, 0.5 mL of DNS solution was added to each tube and boiled for 15 min to stop the reaction. Acarbose was used as a control. Each group was repeated three times. After the liquid in the centrifuge tube returned to room temperature, 200 μL was aspirated from each tube and placed in a 96-well plate. The absorbance value of each well was recorded at 540 nm with an enzyme-labeling instrument and the inhibition rate was calculated according to the formula. 0.4 mL of α-glucosidase (0.5 U / mL) and 0.05 mL of ginsenosides were successively added to a 15 mL centrifuge tube and kept at 37 °C for 15 min. Then 0.4 mL of PNPG solution (5 mmol / L) was added and kept at 37 °C for 30 min. After that, 1 mL of NaCO 3 solution (1 mol / L) was added to each tube to stop the reaction. Acarbose was used as a control. Each group was repeated three times. After the experiment stopped, 200 μL of the reacted liquid was aspirated from each tube and placed in a 96-well plate. The absorbance value of each well was recorded at 405 nm with an enzyme-labeling instrument to calculate the inhibition rate.

[0044] First prepare 100mL 5mM sodium acetate solution (containing 1% Triton-X 100, pH 5.0), then accurately weigh 0.08g lauric acid 4-nitrophenyl ester and dissolve it in it, shake and mix to obtain the substrate working solution, and place it in a 4℃ refrigerator for use. Put it in a boiling water bath for 2 minutes to fully dissolve before use, and cool to room temperature. Take 1g of porcine pancreatic lipase and dissolve it in water. After it is dissolved in the aqueous solution, transfer it to a 100mL volumetric flask to make up the volume. Then centrifuge at 12000rpm for 10min, take the supernatant, and obtain the enzyme solution, which is placed in a -20℃ refrigerator for use. Accurately weigh 0.01g of the three extracts of yellow tea in each beaker, add water to dissolve. Transfer it to a 10mL volumetric flask and make up the volume, and the sample concentration is 1000μg / mL. Place it in a 4℃ refrigerator for use. Accurately pipette 50μL of sample solution of different concentrations (100, 200, 400, 800, 1000μg / mL) into a test tube, then add 150μL of porcine pancreatic lipase solution and 350μL of buffer solution respectively, preheat at 37℃ for 10min, then add 450μL of substrate solution, mix thoroughly and place in a 37℃ oven for reaction for 2h. Subsequently, centrifuge at 12000rpm for 10min, take the supernatant, set up three groups in parallel, and measure the absorbance at 405nm. The control group uses buffer solution instead of enzyme solution. Take 1mL of sample (concentration of 100, 200, 400, 800, 1000μg / mL) into a stoppered test tube, add 1mL of simulated gastric fluid and mix, incubate in a 37℃ water bath environment for 1h, adjust the solution pH to 6.3 with 0.1mol / L sodium hydroxide solution, quickly add 4mL of simulated intestinal fluid to the test tube, and continue to incubate in a 37℃ water bath for 1h. Each sample concentration was added with an equal amount of 4 mL of bile salt solution (1 mg / mL pig bile salt or 0.1 mmol / L sodium glycocholate), and the reaction was continued in a 37°C water bath for 1 hour. After the reaction, the mixture was centrifuged at 4500 r / min for 25 minutes, 1 mL of the supernatant was taken and added with 3 times the volume of 60% concentrated sulfuric acid to terminate the reaction, and the sample was cooled in a 70°C water bath for 20 minutes, and the sample absorbance was measured at an ultraviolet wavelength of 387 nm. The bile salt content in the supernatant was calculated, and the remaining amount of bile salt was calculated according to the pig bile salt and sodium glycocholate standard curves. The binding amount of Dendrobium officinale polysaccharide to bile salt was calculated by the formula.

[0045] Figure 1 The results show that ginsenosides and perilla seed extracts have inhibitory effects on α-amylase and α-glucosidase.

[0046] Example 2

[0047] Lipid accumulation index detection

[0048] Canine hepatocytes were cultured in M-3 cell culture medium containing 10% fetal bovine serum and 5% CO.2 1. Incubate the cells in a 37°C incubator until 80% of them adhere to the wall. Digest and passage the cells using 0.25% trypsin-EDTA, and continue to grow adherently. Inoculate the cells into a six-well plate. When the cells grow to 80% confluence, aspirate the cell culture medium, wash three times with phosphate buffer (PBS, pH = 7.4), then add the medium containing 0.5 mM OA and incubate for 48 h to establish a high-fat cell model, which serves as the negative control; add the medium containing a mixture of 0.5 mM OA, 50 μg / mL ginsenoside, and 25 μg / mL perilla seed extract as the experimental group; the untreated six-well plate serves as the blank control. After culturing all groups for 48 h, lyse the cells with lysis buffer and detect the indicators using TC, TG, HDL-C, and LDL-C kits. Perform Oil Red O staining. The Oil Red staining results of ginsenoside, perilla seed extract, and the composition on the high-fat cell model in the present invention show that there are a large number of red lipid droplets in the negative control group (OA treatment). The red lipid droplets in each experimental group are reduced to varying degrees. This indicates that the two active substances can reduce the excessive lipid accumulation induced by high fat.

[0049] Figure 2 This is the effect of the combination of ginsenoside and perilla seed extract in the present invention on lipid accumulation. The results show that the negative control (OA treatment) can increase the intracellular concentrations of TC, TG, and LDL-C, and decrease the intracellular concentration of HDL-C, resulting in excessive lipid accumulation. After treating the cells with different concentrations of ginsenoside, perilla seed extract, and the composition respectively, the concentrations of TC, TG, and LDL-C decrease, and the concentration of HDL-C increases, which can alleviate the excessive lipid accumulation induced by OA. Moreover, when ginsenoside and perilla seed extract are compounded, the lipid-lowering effect is better, indicating that the combination of the two substances has a synergistic effect.

[0050] Example 3

[0051] Detection of glucose consumption

[0052] Culture and passage the cells according to Example 2. Inoculate the cells in the logarithmic growth phase into a 6-well plate. When the cells grow to 80% confluence, add the basal medium without serum to starve the cells for 24 h. Aspirate the cell culture medium, wash three times with phosphate buffer (PBS, pH = 7.4), then add the high-glucose medium containing 100 mM glucose to establish a high-glucose injury model, which serves as the negative control; add the medium containing a mixture of 100 mM glucose and 50 μg / mL ginsenoside, and 50 μg / mL perilla seed extract respectively as the experimental group; the untreated six-well plate serves as the blank control. After culturing all groups for 48 h, aspirate the cell culture medium, wash with phosphate buffer (PBS, pH = 7.4), then add the complete medium and culture for 24 h. Detect the glucose content in the medium using a GLU kit to calculate the glucose consumption of each group of cells.

[0053] Figure 3 This is the effect of the combination of ginsenosides and perilla seed extract on the glucose consumption of canine hepatocytes in the present invention. The glucose consumption of cells in the negative control group (induced by high glucose) decreased significantly, while the glucose consumption in the groups treated with ginsenosides and perilla seed extract increased.

[0054] Example 4

[0055] Detection of oxidative stress indices

[0056] Cells were passaged according to Example 2. Cells in the logarithmic growth phase were seeded into 6-well plates. When the cells reached 80% confluence, they were starved in serum-free medium for 24 h. After co-culturing with high glucose and active substances for 48 h, the cell culture medium was washed away, and the cells were washed three times with phosphate buffer (PBS, pH = 7.4). The cells were lysed, and oxidative stress indices were detected using SOD, MDA, and CAT assay kits.

[0057] The DCFH-DA probe was diluted with serum-free culture medium at a ratio of 1:500 to a final concentration of 10 μmol / L. DCFH-DA is a commonly used ROS fluorescent probe that can enter cells and be hydrolyzed by esterase in cells into DCFH, and then DCFH can be oxidized by reactive oxygen species in cells to generate fluorescent DCF. The original cell culture medium was removed, and an appropriate amount of diluted DCFH-DA was added to ensure coverage of the cell layer (50 μl per well for 96-well plates and 1 ml per well for 6-well plates). Incubate in a 37 °C cell culture incubator for 20 minutes to allow the probe to fully penetrate the cells. Wash the cells three times with serum-free cell culture medium to remove DCFH-DA that did not enter the cells. Take pictures and record using a fluorescence microscope.

[0058] Figure 4 This is the effect of the combination of ginsenosides and perilla seed extract on the oxidative stress indices of canine hepatocytes damaged by high glucose induction in the present invention. The results showed that ginsenosides, perilla seed extract, and their combination alleviated oxidative stress in cells damaged by high glucose to varying degrees.

[0059] Example 5

[0060] To deeply understand the effects of ginsenosides, perilla seed extract, and their combination on reducing blood sugar and lipid levels in pets, transcriptomic sequencing of cell RNA and non-target metabolome analysis were performed based on the Illumina sequencing platform. Cells were treated according to the methods of Example 2 and Example 3. Equal volumes of samples were taken from each experimental sample and mixed as a quality control group. RNA was extracted from each group using standard methods, libraries were constructed, and sequencing was performed on the machine. The DESeq2 software (1.20.0) was used for differential expression analysis between two comparison groups.

[0061] Figure 5It is a volcano plot and a bar chart of differentially expressed genes among groups. The results show that compared with the negative control group (oleic acid-induced hyperlipidemia), there are 3,833 up-regulated genes and 4,293 down-regulated genes in the active substance composition treatment group. Compared with the group treated only with ginsenosides, there are 86 up-regulated genes and 236 down-regulated genes in the active substance composition. Compared with the negative control (high glucose-induced injury), there are 3,057 up-regulated genes and 3,417 down-regulated genes in the perilla seed extract treatment group. The differentially expressed genes were annotated and enriched in the Gene Ontology (GO) database. The results show that entries such as cellular localization, vesicle-mediated transport, intracellular protein localization, cytoplasmic part, mitochondrion, organelle membrane, endomembrane system, ubiquitin-protein transferase activity, and enzyme binding were significantly enriched. The enrichment results in the Kyoto Encyclopedia of Genes and Genomes (KEGG) database show that the perilla seed extract affects pathways such as autophagy, protein synthesis, non-alcoholic fatty liver disease, and mitophagy. Ginsenosides affect pathways such as endocytosis, lysosome, protein transport, and miRNAs in cancer. The active substance composition mainly affects pathways such as endocytosis, digestive tract tumors, the MAPK signaling pathway (mitogen-activated protein kinase), the p53 signaling pathway (apoptosis, senescence-related), and the mRNA surveillance pathway. These pathways play important roles in processes such as cell movement, cell proliferation, cell differentiation, and cell survival. Therefore, ginsenosides and perilla seed extract alleviate the damage of high fat and high sugar to cells by affecting the expression of genes or enzymes in these pathways.

[0062] Example 6

[0063] This example provides a preparation method of a nutritional supplement for improving pet obesity, which is carried out according to the following steps:

[0064] Step (1): Weigh 1 part of ginsenosides and 0.5 part of perilla seed extract and mix them. Stir with a blender at a speed of 300 r / min for 20 min, and pass through a 100-mesh sieve to obtain a mixed powder.

[0065] Step (2): Add water to the mixed powder, and stir the raw and auxiliary materials and glyceryl monostearate with a homogenizer at a speed of 11,000 r / min for 4 min to obtain a raw and auxiliary material mixture.

[0066] Step (3): Directly compress the raw and auxiliary material mixture with a rotary tablet press to obtain 200 nutritional supplement tablets.

[0067] In step (2), the raw materials are 80 parts of chicken powder, 5 parts of mulberry leaf powder, 4 parts of hawthorn powder, 2 parts of propolis, and 6 parts of water.

[0068] In step (2), the auxiliary materials are 0.1 part of glutamic acid, 0.01 part of vitamin C, 0.05 part of α-linolenic acid, 0.01 part of EPA (eicosapentaenoic acid), 0.02 part of vitamin A, and 0.2 part of glycerol monostearate.

[0069] Example 7

[0070] This example provides a preparation method of a nutritional supplement for improving pet obesity, which is carried out according to the following steps:

[0071] Step (1): Weigh 1.2 parts of ginsenoside and 0.4 part of perilla seed extract and mix them. Stir with a blender at a speed of 300 r / min for 20 min, and pass through a 100-mesh sieve to obtain a mixed powder.

[0072] Step (2): Add water to the mixed powder, and stir the raw and auxiliary materials and glycerol monostearate with a homogenizer at a speed of 11000 r / min for 4 min to obtain a raw and auxiliary material mixture.

[0073] Step (3): Directly press the raw and auxiliary material mixture with a rotary tablet press to obtain 200 nutritional supplement tablets.

[0074] In step (2), the raw materials are 100 parts of chicken powder, 3 parts of mulberry leaf powder, 3 parts of hawthorn powder, 1 part of propolis, and 8 parts of water.

[0075] In step (2), the auxiliary materials are 0.2 part of glutamic acid, 0.02 part of vitamin C, 0.05 part of α-linolenic acid, 0.02 part of EPA (eicosapentaenoic acid), 0.02 part of vitamin A, and 0.2 part of glycerol monostearate.

[0076] Example 8

[0077] This example provides a preparation method of a nutritional supplement for improving pet obesity, which is carried out according to the following steps:

[0078] Step (1): Weigh 1 part of ginsenoside and 0.8 part of perilla seed extract and mix them. Stir with a blender at a speed of 200 r / min for 15 min, and pass through a 100-mesh sieve to obtain a mixed powder.

[0079] Step (2): Add water to the mixed powder, and stir the raw and auxiliary materials and glycerol monostearate with a homogenizer at a speed of 11000 r / min for 4 min to obtain a raw and auxiliary material mixture.

[0080] Step (3): Directly press the raw and auxiliary material mixture with a rotary tablet press to obtain 200 nutritional supplement tablets.

[0081] In step (2), the raw materials are 80 parts of chicken powder, 5 parts of mulberry leaf powder, 4 parts of hawthorn powder, 1 part of propolis, and 8 parts of water.

[0082] In step (2), the auxiliary materials are 0.1 part of glutamic acid, 0.01 part of vitamin C, 0.03 part of α-linolenic acid, 0.01 part of EPA (eicosapentaenoic acid), 0.02 part of vitamin A, and 0.2 part of glycerol monostearate.

[0083] Effect test examples

[0084] 1. Test method

[0085] Test animals and grouping: Select 24 overweight cats (dogs) each, and randomly divide them into 6 groups with 4 in each group.

[0086] 2. Intervention plan: Groups 1-3 are experimental groups 1-3, which are fed a basal diet daily, and at the same time, the nutritional supplement tablets prepared in Examples 6-8 are fed daily respectively. Groups 4-6 are control groups, which are fed a basal diet daily, and at the same time, the nutritional supplement tablets prepared by adding no ginsenoside and perilla seed extract in the experimental groups are fed daily respectively. The other components of the nutritional tablets in each group are the same as those in Examples 6, 7, and 8 respectively. The dosage of the nutritional tablets fed in each group is 2 tablets each time, 2 times a day, and fed continuously for 30 days. Observe the activity conditions, and after 30 days, collect blood to detect total cholesterol TC and triglyceride TG respectively.

[0087] 3. Test results

[0088] The effects of each group of cats and dogs are shown in Tables 1 and 2. Compared with the control group, feeding experimental groups 1-3 (corresponding to Examples 6-8) can significantly reduce the total cholesterol and triglyceride contents of overweight cats (dogs).

[0089] Table 1 Measurement results of blood lipid indexes of each group of cats

[0090]

[0091] Table 2 Measurement results of blood lipid indexes of each group of dogs

[0092]

Claims

1. An active substance composition for lowering blood sugar and blood lipids in dogs and cats, characterized in that The active substance composition is composed of ginsenoside and perilla seed extract; the weight ratio of the two raw materials of ginsenoside and perilla seed extract in the active substance composition is: ginsenoside: perilla seed extract = 2: (1-1.5).

2. The active substance composition for lowering blood sugar and blood lipids in dogs and cats according to claim 1, characterized in that The weight ratio of the two raw materials, ginsenoside and perilla seed extract, in the active substance composition is: ginsenoside: perilla seed extract = 2:

1.

3. Use of an active substance composition for lowering blood sugar and blood lipids in dogs and cats as claimed in claim 1 or claim 2 in the preparation of pet feed or pet health products.

4. Use of an active substance composition for lowering blood sugar and blood lipids in dogs and cats as claimed in claim 1 or claim 2 in the preparation of pet feed and pet health products for lowering blood lipids in dogs and cats.

5. Use of an active substance composition for lowering blood sugar and blood lipids in dogs and cats as claimed in claim 1 or claim 2 in the preparation of pet feed and pet health products for lowering blood sugar in dogs and cats.

6. Use of an active substance composition for lowering blood sugar and blood lipids in dogs and cats as claimed in claim 1 or claim 2 in the preparation of pet feed and pet health products for improving obesity in dogs and cats.

7. The active substance composition for lowering blood sugar and blood lipids in dogs and cats according to claim 1 or claim 2 is used as a nutritional supplement for improving obesity in pets, characterized in that It is composed of ginsenoside, perilla seed extract, chicken powder, mulberry leaf powder, hawthorn powder and honeycomb; the mass fractions of each component are: 0.5-2 parts of ginsenoside, 0.5-1 parts of perilla seed extract, 70-80 parts of chicken powder, 8-12 parts of mulberry leaf powder, 8-10 parts of hawthorn powder, 0.01-0.03 parts of honeycomb, 0.1-0.3 parts of glutamic acid, 0.01-0.03 parts of vitamin C, 0.5-0.7 parts of α-linolenic acid, and 0.01-0.04 parts of eicosapentaenoic acid.

8. The method for preparing the nutritional supplement for improving pet obesity according to claim 7, characterized in that Follow the steps below: Step (1): weighing ginsenoside and perilla seed extract in a ratio of 1:1.5, mixing them, stirring them at 300 r / min in a blender for 20 min, and passing them through a 100-mesh sieve to obtain a mixed powder; Step (2): adding water to the mixed powder, stirring the raw material and glyceryl monostearate with the raw material and auxiliary material using a homogenizer at a speed of 11000 r / min for 4 minutes to obtain a raw material and auxiliary material mixture; Step (3): directly tableting the raw material and auxiliary material mixture using a rotary tablet press, The raw materials in step (2) are 80 parts of chicken powder, 5 parts of mulberry leaf powder, 4 parts of hawthorn powder, 0.02 parts of honeycomb, and 6 parts of water; The auxiliary materials in step (2) are 0.1 parts of glutamic acid, 0.01 parts of vitamin C, 0.05 parts of α-linolenic acid, 0.01 parts of eicosapentaenoic acid, 0.02 parts of vitamin A, and 0.2 parts of glyceryl monostearate.

Images